Merck Manual

Please confirm that you are a health care professional


Overview of Thrombotic Disorders


Joel L. Moake

, MD, Baylor College of Medicine

Last full review/revision Aug 2019| Content last modified Aug 2019
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

In healthy people, homeostatic balance exists between procoagulant (clotting) forces and anticoagulant and fibrinolytic forces. Numerous genetic, acquired, and environmental factors can tip the balance in favor of coagulation, leading to the pathologic formation of thrombi in veins (eg, deep venous thrombosis [DVT]), arteries (eg, myocardial infarction, ischemic stroke), or cardiac chambers. Thrombi can obstruct blood flow at the site of formation or detach and embolize to block a distant blood vessel (eg, pulmonary embolism, embolic stroke).


Genetic defects that increase the propensity for venous thromboembolism include

Acquired defects also predispose to venous and arterial thrombosis (see table Acquired Causes of Thromboembolism).

Other disorders and environmental factors can increase the risk of thrombosis, especially if a genetic abnormality is also present.


Acquired Causes of Thromboembolism



Autoimmune disorder with increased risk of venous or arterial thrombi

Increases risk of arterial thrombi

Higher risk in patients with preexisting stenosis

When atherosclerotic plaques rupture, they expose or release tissue factor, activate coagulation, initiate local platelet adhesion and aggregation, and cause thrombosis

Cancer (promyelocytic leukemia; lung, breast, prostate, pancreas, stomach, and colon tumors)

May activate coagulation by secreting a factor X–activating protease, by expressing/exposing tissue factor on membrane surfaces, or both

Associated with platelet aggregation and increased risk of thrombosis

Possible cause

Due to folate, vitamin B12, or vitamin B6 deficiency

Infection, if severe (eg, sepsis)

Increases risk of venous thrombosis

Increases expression/exposure of tissue factor by monocytes and macrophages

Decreases formation of activated protein C

Oral contraceptives that contain estrogen

Low risk with low-dose regimens

More frequent in patients who have a genetic abnormality that predisposes to venous thromboembolism, and in women who smoke

Tissue injury

Due to trauma or surgery

Venous stasis

Due to surgery, orthopedic or paralytic immobilization, heart failure, pregnancy, or obesity

Symptoms and Signs

Common manifestations of a thrombotic disorder include unexplained deep venous thrombosis and pulmonary embolism (PE). Superficial thrombophlebitis can also develop. Other consequences may include arterial thrombosis (eg, causing stroke or mesenteric ischemia). Symptoms depend on the location of the clot, as in the following examples:

  • Chest pain and shortness of breath: Possible PE

  • Leg warmth, redness, and swelling: DVT

  • Weakness/numbness of one side of the body, problems speaking, and problems with balance and walking: Possible ischemic stroke

  • Abdominal pain: Possible mesenteric ischemia

Most of the inherited disorders do not begin to cause an increased risk of clotting until young adulthood, although clots can form at any age. Women may have a history of multiple spontaneous abortions.


Diagnoses are summarized elsewhere in THE MANUAL specific to the location of the thrombus (eg, deep venous thrombosis, pulmonary embolism, ischemic stroke).

Predisposing factors

Predisposing factors should always be considered. In some cases, the condition is clinically obvious (eg, recent surgery or trauma, prolonged immobilization, cancer, generalized atherosclerosis). If no predisposing factor is readily apparent, further evaluation should be conducted in patients with

  • Family history of venous thrombosis

  • More than one episode of venous thrombosis

  • Venous or arterial thrombosis before age 50

  • Unusual sites of venous thrombosis (eg, cavernous sinus, mesenteric veins)

As many as half of all patients with spontaneous DVT have a genetic predisposition.

Testing for predisposing congenital factors includes specific assays that measure the quantity or activity of natural anticoagulant molecules in plasma, and screening for specific gene defects, as follows:

  • Clotting assay for lupus anticoagulant

  • Clotting assay for resistance to activated protein C

  • Genetic test for factor V Leiden

  • Genetic test for prothrombin gene mutation (G20210A)

  • Functional assay of antithrombin

  • Functional assay of protein C

  • Functional assay of protein S

  • Antigenic assays of total and free protein S.

  • Measurement of plasma homocysteine levels

  • Immunoassays for antiphospholipid antibodies


Treatment is summarized elsewhere in THE MANUAL specific to the location of the thrombus.

Anticoagulation is often required, typically beginning with parenteral heparin or low molecular weight heparin, and then followed by oral warfarin or one of the direct oral anticoagulants (DOACs). Drugs include factor Xa inhibitors (rivaroxabanapixabanedoxaban) and a direct thrombin inhibitor (dabigatran). Unlike warfarin, the direct oral anticoagulants do not require regular laboratory monitoring,. DOACs can be reversed either by time (they have brief in vivo half-lives) or in some cases by recently developed agents (idaricizumab for dabigatran; andexanet for rivaroxaban or apixaban [1, 2]).

A major current disadvantage of DOACs is their expense.

Treatment references

Drugs Mentioned In This Article

Drug Name Select Trade
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version

Also of Interest


View All
Bone Marrow Biopsy
Bone Marrow Biopsy
Overview of Hemochromatosis
Overview of Hemochromatosis